Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial
Authors
Keywords
Cardiovascular disease, Coronary artery bypass graft, Coronary revascularisation, Diabetes mellitus, Empagliflozin, Sodium glucose cotransporter 2 inhibition, Type 2 diabetes
Journal
DIABETOLOGIA
Volume 61, Issue 8, Pages 1712-1723
Publisher
Springer Nature
Online
2018-05-19
DOI
10.1007/s00125-018-4644-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial?
- (2017) Xingjuan Shi et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
- (2017) David Z I Cherney et al. Lancet Diabetes & Endocrinology
- The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition
- (2017) Subodh Verma et al. JAMA Cardiology
- Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease
- (2017) Subodh Verma et al. CIRCULATION
- Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update
- (2016) Gillian Booth et al. Canadian Journal of Diabetes
- Empagliflozin’s Fuel Hypothesis: Not so Soon
- (2016) Gary D. Lopaschuk et al. Cell Metabolism
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
- (2016) Hiddo J.L. Heerspink et al. CIRCULATION
- Acute Pharmacodynamic Effects of Empagliflozin With and Without Diuretic Agents in Patients With Type 2 Diabetes Mellitus
- (2016) Tim Heise et al. CLINICAL THERAPEUTICS
- Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes
- (2016) Tim Heise et al. CLINICAL THERAPEUTICS
- Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?
- (2016) Subodh Verma et al. DIABETES CARE
- 8. Pharmacologic Approaches to Glycemic Treatment
- (2016) DIABETES CARE
- SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
- (2016) Naveed Sattar et al. DIABETOLOGIA
- Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
- (2016) Antonius Baartscheer et al. DIABETOLOGIA
- Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial
- (2016) David Fitchett et al. EUROPEAN HEART JOURNAL
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Secondary Prevention After Coronary Artery Bypass Graft Surgery: A Scientific Statement From the American Heart Association
- (2015) A. Kulik et al. CIRCULATION
- Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes
- (2015) Petar M. Seferović et al. EUROPEAN HEART JOURNAL
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
- (2013) David Z.I. Cherney et al. CIRCULATION
- ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2013) EUROPEAN HEART JOURNAL
- Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial†
- (2013) Arie Pieter Kappetein et al. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
- Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: a meta-analysis of randomised controlled trials
- (2013) Subodh Verma et al. Lancet Diabetes & Endocrinology
- Differences in Prevalence, Extent, Severity, and Prognosis of Coronary Artery Disease Among Patients With and Without Diabetes Undergoing Coronary Computed Tomography Angiography: Results from 10,110 individuals from the CONFIRM (COronary CT Angiography EvaluatioN For Clinical Outcomes): an InteRnational Multicenter Registry
- (2012) J. S. Rana et al. DIABETES CARE
- Incidence and trends of heart failure admissions after coronary artery bypass grafting surgery
- (2012) Abel E. Moreyra et al. EUROPEAN JOURNAL OF HEART FAILURE
- Strategies for Multivessel Revascularization in Patients with Diabetes
- (2012) Michael E. Farkouh et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Angiotensin-Converting Enzyme Inhibition in Low-Risk Patients Early After Coronary Artery Bypass Surgery
- (2007) Jean L. Rouleau et al. CIRCULATION
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started